AI measurement of prostate cancer spread on PSMA PET-CT scans
Studies whether AI-measured tumour amount on scans predicts survival in men with prostate cancer.
Plain-language title generated from the registry record
Registry title: AI-based Measurements of Tumour Burden in PSMA PET-CT
Key facts
- Where
- Lund and Malmö, SwedenSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 120 years old?
Source: NCT06363435, who can take part
Where in Sweden
- Skåne University HospitalLund, SwedenTaking people
- Skåne University HospitalMalmö, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Elin Tragardh
- Trial code
- NCT06363435
- Record updated
- 28 April 2026
- Original description
The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).Read full original descriptionShow less
The Prognostic Value of AI-based Measurements of Tumour Burden in PSMA PET-CT in Patients With Prostate Cancer
The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).
Inclusion: Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden.
Exclusion: Patients under 20 years old.